Published in J Virol on August 01, 2001
Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol (2003) 3.97
Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev (2002) 2.86
The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev (2013) 2.28
Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc Natl Acad Sci U S A (2002) 2.15
Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev (2009) 1.90
Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe (2010) 1.77
Human cytomegalovirus gene expression is silenced by Daxx-mediated intrinsic immune defense in model latent infections established in vitro. J Virol (2007) 1.60
Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. J Immunol (2008) 1.48
Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. J Virol (2003) 1.44
Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus. J Virol (2009) 1.29
Cellular and viral control over the initial events of human cytomegalovirus experimental latency in CD34+ cells. J Virol (2010) 1.29
Epstein-Barr virus (EBV)-infected monocytes facilitate dissemination of EBV within the oral mucosal epithelium. J Virol (2007) 1.26
Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency. Med Microbiol Immunol (2007) 1.20
Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virol (2003) 1.18
Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination. Blood (2005) 1.15
Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells. PLoS Pathog (2013) 1.12
A myeloid progenitor cell line capable of supporting human cytomegalovirus latency and reactivation, resulting in infectious progeny. J Virol (2012) 1.07
Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration. J Virol (2011) 1.07
Viral interleukin-10 expressed by human cytomegalovirus during the latent phase of infection modulates latently infected myeloid cell differentiation. J Virol (2011) 1.06
Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma. Virol J (2005) 1.04
Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J Virol (2003) 1.01
Reversal of human cytomegalovirus major immediate-early enhancer/promoter silencing in quiescently infected cells via the cyclic AMP signaling pathway. J Virol (2007) 1.01
Human cytomegalovirus infection of M1 and M2 macrophages triggers inflammation and autologous T-cell proliferation. J Virol (2012) 0.99
Tegument protein control of latent herpesvirus establishment and animation. Herpesviridae (2011) 0.98
Monocytes as regulators of inflammation and HIV-related comorbidities during cART. J Immunol Res (2014) 0.98
Impact of human cytomegalovirus latent infection on myeloid progenitor cell gene expression. J Virol (2004) 0.97
cGAS Senses Human Cytomegalovirus and Induces Type I Interferon Responses in Human Monocyte-Derived Cells. PLoS Pathog (2016) 0.95
Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-γ. PLoS Pathog (2011) 0.95
Cytomegalovirus hijacks CX3CR1(hi) patrolling monocytes as immune-privileged vehicles for dissemination in mice. Cell Host Microbe (2014) 0.94
Human cytomegalovirus induction of a unique signalsome during viral entry into monocytes mediates distinct functional changes: a strategy for viral dissemination. J Leukoc Biol (2012) 0.94
HCMV protein LUNA is required for viral reactivation from latently infected primary CD14⁺ cells. PLoS One (2012) 0.92
The DNA damage response induced by infection with human cytomegalovirus and other viruses. Viruses (2014) 0.90
Human cytomegalovirus inhibits cytokine-induced macrophage differentiation. J Virol (2004) 0.90
Human cytomegalovirus paralyzes macrophage motility through down-regulation of chemokine receptors, reorganization of the cytoskeleton, and release of macrophage migration inhibitory factor. J Immunol (2009) 0.90
Human cytomegalovirus subverts the functions of monocytes, impairing chemokine-mediated migration and leukocyte recruitment. J Virol (2006) 0.90
Infection with human cytomegalovirus alters the MMP-9/TIMP-1 balance in human macrophages. J Virol (2008) 0.89
Cytomegalovirus enhances macrophage TLR expression and MyD88-mediated signal transduction to potentiate inducible inflammatory responses. J Immunol (2014) 0.89
Cytomegalovirus CC chemokine promotes immune cell migration. J Virol (2012) 0.87
Human Cytomegalovirus Latency: Approaching the Gordian Knot. Annu Rev Virol (2016) 0.86
The intimate relationship between human cytomegalovirus and the dendritic cell lineage. Front Microbiol (2014) 0.85
Rab27a is required for human cytomegalovirus assembly. PLoS One (2010) 0.85
Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis. Infect Disord Drug Targets (2011) 0.85
HCMV reprogramming of infected monocyte survival and differentiation: a Goldilocks phenomenon. Viruses (2014) 0.85
Dendritic cell biology in human cytomegalovirus infection and the clinical consequences for host immunity and pathology. Virulence (2012) 0.84
Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls. PLoS One (2014) 0.84
Transmission of murine cytomegalovirus in breast milk: a model of natural infection in neonates. J Virol (2011) 0.82
Learning in a simple biological system: a pilot study of classical conditioning of human macrophages in vitro. Behav Brain Funct (2011) 0.81
Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients. J Gen Virol (2014) 0.80
Functional genomics approaches to understand cytomegalovirus replication, latency and pathogenesis. Curr Opin Virol (2013) 0.80
Recognition of a novel stage of betaherpesvirus latency in human herpesvirus 6. J Virol (2003) 0.79
Functional annotation of human cytomegalovirus gene products: an update. Front Microbiol (2014) 0.79
The Expression of Human Cytomegalovirus MicroRNA MiR-UL148D during Latent Infection in Primary Myeloid Cells Inhibits Activin A-triggered Secretion of IL-6. Sci Rep (2016) 0.79
Bioactive Molecules Released From Cells Infected with the Human Cytomegalovirus. Front Microbiol (2016) 0.79
Broncholaveolar lavage to detect cytomegalovirus infection, latency, and reactivation in immune competent hosts. J Med Virol (2016) 0.77
Differentiation-Coupled Induction of Human Cytomegalovirus Replication by Union of the Major Enhancer Retinoic Acid, Cyclic AMP, and NF-κB Response Elements. J Virol (2015) 0.77
The human cytomegalovirus lytic cycle is induced by 1,25-dihydroxyvitamin D3 in peripheral blood monocytes and in the THP-1 monocytic cell line. Virology (2015) 0.76
Opposing Regulation of the EGF Receptor: A Molecular Switch Controlling Cytomegalovirus Latency and Replication. PLoS Pathog (2016) 0.76
HCMV requires EGFR signaling to enter and initiate the early steps in the establishment of latency in CD34+ human progenitor cells. J Virol (2016) 0.76
HCMV Displays a Unique Transcriptome of Immunomodulatory Genes in Primary Monocyte-Derived Cell Types. PLoS One (2016) 0.76
Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein. Nat Commun (2017) 0.75
Cytomegalovirus (CMV) Infection Causes Degeneration of Cochlear Vasculature and Hearing Loss in a Mouse Model. J Assoc Res Otolaryngol (2016) 0.75
Identification of transcription factor AML-1 binding site upstream of human cytomegalovirus UL111A gene. PLoS One (2015) 0.75
Role of cytomegalovirus on the maturation and function of monocyte derived dendritic cells of liver transplant patients. World J Transplant (2016) 0.75
Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity. Hum Vaccin Immunother (2017) 0.75
Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol (1991) 4.61
Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell (1997) 3.99
Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J Virol (1989) 3.98
Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. J Exp Med (1995) 3.40
Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis (1986) 3.31
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci U S A (1994) 3.03
Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci U S A (1996) 2.87
Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol (1994) 2.68
Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol (1992) 2.67
The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections. J Virol (1995) 2.45
Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol (1997) 2.35
Human cytomegalovirus infection of the monocyte/macrophage lineage in bone marrow. J Virol (1994) 2.31
Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization. J Infect Dis (1990) 2.08
Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages. J Virol (1991) 2.07
Interferon gamma regulates acute and latent murine cytomegalovirus infection and chronic disease of the great vessels. J Exp Med (1998) 2.04
Phorbol ester-induced differentiation permits productive human cytomegalovirus infection in a monocytic cell line. J Immunol (1988) 2.01
Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol (1994) 1.89
Dendritic cells as the terminal stage of monocyte differentiation. J Immunol (1998) 1.87
Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol (1994) 1.71
Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med (1986) 1.71
Human cytomegalovirus immediate early and late transcripts are expressed in all major leukocyte populations in vivo. J Infect Dis (1995) 1.70
Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest (1997) 1.62
Repression of human cytomegalovirus major immediate early gene expression in a monocytic cell line. J Gen Virol (1992) 1.57
Growth kinetics of human cytomegalovirus are altered in monocyte-derived macrophages. J Virol (1995) 1.52
Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol (1993) 1.51
Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol (1993) 1.48
Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116). J Virol (1992) 1.42
Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol (1988) 1.41
A novel mechanism for persistence of human cytomegalovirus in macrophages. J Virol (1996) 1.37
Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol (1993) 1.33
Infection of mononucleated phagocytes with human cytomegalovirus. Virology (1993) 1.23
Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis (1989) 1.22
Cell types infected in human cytomegalovirus placentitis identified by immunohistochemical double staining. Virchows Arch A Pathol Anat Histopathol (1993) 1.17
Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells. J Gen Virol (1995) 1.12
Cytomegalovirus persistence in macrophages and endothelial cells. Scand J Infect Dis Suppl (1995) 1.09
Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells. Cytokine (2000) 1.04
IL-2 induces IL-6 production in human monocytes. J Immunol (1992) 1.03
Interleukin-2-induced tumor necrosis factor-alpha (TNF-alpha) gene expression in human alveolar macrophages and blood monocytes. Am Rev Respir Dis (1989) 0.97
Transfusion-transmitted cytomegalovirus infection. Hematol Oncol Clin North Am (1995) 0.96
Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant (1996) 0.90
A European multicenter study of chronic graft-versus-host disease. The role of cytomegalovirus serology in recipients and donors--acute graft-versus-host disease, and splenectomy. Transplantation (1990) 0.88
Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplantation (1996) 0.88
Secretion of cytokines upon allogeneic stimulation: effect of aging. J Biol Regul Homeost Agents (1995) 0.88
Cytomegalovirus infection as a complication of blood transfusion. Semin Liver Dis (1986) 0.87
Cytomegalovirus infection and reinfection transmitted by heart transplantation. J Infect Dis (1987) 0.86
Differential effects of interleukin-13 on cytomegalovirus and human immunodeficiency virus infection in human alveolar macrophages. Blood (1997) 0.86
The association of the induction of vascular cell adhesion molecule-1 with cytomegalovirus antigenemia in human heart allografts. Transplantation (1993) 0.85
Expression of adhesion molecules and their ligands in liver allografts during cytomegalovirus (CMV) infection and acute rejection. Transpl Int (1996) 0.85
Transmission of cytomegalovirus by pretransplant leukocyte transfusions in renal transplant candidates. J Infect Dis (1987) 0.85
Cytomegalovirus infection in leucocytes after bone marrow transplantation demonstrated by mRNA in situ hybridization. Br J Haematol (1993) 0.81
Enhancing effects of IL-2 on M-CSF production by human peripheral blood monocytes. Int J Hematol (1993) 0.80
'Supernatural' killer cells. Immunol Today (1985) 0.78
Optimal control of interferon-gamma and tumor necrosis factor-alpha by interleukin-10 produced in response to one HLA-DR mismatch during the primary mixed lymphocyte reaction. Transplantation (1996) 0.78
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains. J Virol (1990) 4.24
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell (1997) 3.99
Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J Virol (1989) 3.98
Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science (1985) 3.69
BEACHES: an observational system for assessing children's eating and physical activity behaviors and associated events. J Appl Behav Anal (1991) 3.61
Seven-day recall and other physical activity self-reports in children and adolescents. Med Sci Sports Exerc (1993) 3.57
Widespread presence of histologically occult cytomegalovirus. Hum Pathol (1984) 3.45
Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol (1997) 3.38
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A (1996) 3.17
Human cytomegalovirus productively infects primary differentiated macrophages. J Virol (1991) 3.16
Predominant immediate-early transcripts of human cytomegalovirus AD 169. J Virol (1984) 3.15
Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8. J Virol (1999) 3.02
The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell (1999) 2.97
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol (1987) 2.97
Correlates of physical activity at home in Mexican-American and Anglo-American preschool children. Health Psychol (1993) 2.74
Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med (1990) 2.45
The Sar1 GTPase coordinates biosynthetic cargo selection with endoplasmic reticulum export site assembly. J Cell Biol (2001) 2.41
Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype. Proc Natl Acad Sci U S A (1991) 2.38
The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol (1996) 2.37
Restoration of telomeres in human papillomavirus-immortalized human anogenital epithelial cells. Mol Cell Biol (1994) 2.26
Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med (1999) 2.08
Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 encephalitis. Am J Pathol (1999) 2.07
Transcriptional regulation of the human cytomegalovirus major immediate-early gene is associated with induction of DNase I-hypersensitive sites. Mol Cell Biol (1986) 2.05
Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol (1997) 2.00
Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood (1996) 1.98
HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet (1997) 1.95
Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. J Neuropathol Exp Neurol (1986) 1.94
The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J Virol (2000) 1.92
Do pathogens accelerate atherosclerosis? J Nutr (2001) 1.91
Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis (1987) 1.91
Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nat Med (1995) 1.90
Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169. J Virol (1982) 1.88
Analysis of methotrexate in human plasma by high-pressure liquid chromatography with fluorescence detection. Cancer Res (1977) 1.87
Human cytomegalovirus IE86 protein interacts with promoter-bound TATA-binding protein via a specific region distinct from the autorepression domain. J Virol (1993) 1.82
Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in transport of gH to the cell surface. Virology (1993) 1.81
Radiographic findings of the National Cooperative Crohn's Disease Study. Gastroenterology (1979) 1.77
Television's influence on children's diet and physical activity. J Dev Behav Pediatr (1989) 1.77
Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism. Proc Natl Acad Sci U S A (1993) 1.73
Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex. J Virol (1997) 1.73
Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. Clin Infect Dis (1998) 1.72
Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta32. J Virol (1998) 1.69
Direct interaction of the human cytomegalovirus IE86 protein with the cis repression signal does not preclude TBP from binding to the TATA box. J Virol (1993) 1.68
Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science (1987) 1.66
Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest (1997) 1.62
A discrete cis element in the human immunodeficiency virus long terminal repeat mediates synergistic trans activation by cytomegalovirus immediate-early proteins. J Virol (1991) 1.62
Interaction of the 72-kilodalton human cytomegalovirus IE1 gene product with E2F1 coincides with E2F-dependent activation of dihydrofolate reductase transcription. J Virol (1995) 1.59
Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. J Virol (1988) 1.57
Energy and macronutrient intakes of elite figure skaters. J Am Diet Assoc (2001) 1.56
Human cytomegalovirus persistently infects aortic endothelial cells. J Virol (1998) 1.55
Aerobic and anaerobic swimming performance of individual Atlantic cod. J Exp Biol (2000) 1.55
Growth kinetics of human cytomegalovirus are altered in monocyte-derived macrophages. J Virol (1995) 1.52
Thermally induced asthma and airway drying. Am J Respir Crit Care Med (1999) 1.52
Gossypiboma--the problem of the retained surgical sponge. Radiology (1978) 1.52
An isoform variant of the cytomegalovirus immediate-early auto repressor functions as a transcriptional activator. Virology (1992) 1.51
Role of human immunodeficiency virus and cytomegalovirus in AIDS encephalitis. Am J Pathol (1988) 1.49
THE MILLER-ABBOTT TUBE AS AN ADJUNCT TO SURGERY OF SMALL INTESTINAL OBSTRUCTIONS. Ann Surg (1940) 1.49
Effects of dichlorodiphenyltrichloroethane (DDT) analogs and polychlorinated biphenyl (PCB) mixtures on 17beta-(3H)estradiol binding to rat uterine receptor. Biochem Pharmacol (1974) 1.48
T cell recognition of HIV synthetic peptides in a natural infection. J Immunol (1989) 1.47
Spatial analysis of the distribution of Ixodes dammini (Acari: Ixodidae) on white-tailed deer in Ogle County, Illinois. J Med Entomol (1992) 1.47
HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. Lancet (1990) 1.45
B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus. J Virol (1988) 1.42
Effect of spectral shaping and content on loudness discomfort. J Am Acad Audiol (2001) 1.42
Inflammatory cells in transplanted kidneys are infected by human cytomegalovirus. Am J Pathol (1988) 1.41
Individual variation and repeatability in aerobic and anaerobic swimming performance of European sea bass, Dicentrarchus labrax. J Exp Biol (2010) 1.39
T-cell-induced expression of human immunodeficiency virus in macrophages. J Virol (1990) 1.38
The Caltrac accelerometer as a physical activity monitor for school-age children. Med Sci Sports Exerc (1990) 1.38
Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol (2000) 1.38
A novel mechanism for persistence of human cytomegalovirus in macrophages. J Virol (1996) 1.37
Structure of the transforming region of human cytomegalovirus AD169. J Virol (1984) 1.35
Small fragments of herpesvirus DNA with transforming activity contain insertion sequence-like structures. Proc Natl Acad Sci U S A (1984) 1.34
Acceptability of self-collection of specimens for HPV DNA testing in an urban population. J Womens Health (Larchmt) (2005) 1.30
Steady-state plasma membrane expression of human cytomegalovirus gB is determined by the phosphorylation state of Ser900. J Virol (1998) 1.29
Site-specific inhibition of RNA polymerase II preinitiation complex assembly by human cytomegalovirus IE86 protein. J Virol (1993) 1.28
Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res (1994) 1.27
Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol (2008) 1.27
Developmental analysis of the cytomegalovirus enhancer in transgenic animals. J Virol (1996) 1.27
A protein-based therapeutic for human cytomegalovirus infection. Proc Natl Acad Sci U S A (2000) 1.23
Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res (1975) 1.23
Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent. J Virol (1999) 1.23
European Lyme borreliosis: 231 culture-confirmed cases involving patients with erythema migrans. Clin Infect Dis (1996) 1.23
Immortalization of primary human smooth muscle cells. Proc Natl Acad Sci U S A (1992) 1.21
24,25-Epoxysterol metabolism in cultured mammalian cells and repression of 3-hydroxy-3-methylglutaryl-CoA reductase. J Biol Chem (1986) 1.21
Enhancement of RNA polymerase II initiation complexes by a novel DNA control domain downstream from the cap site of the cytomegalovirus major immediate-early promoter. J Virol (1991) 1.20
Anglo- and Mexican-American preschoolers at home and at recess: activity patterns and environmental influences. J Dev Behav Pediatr (1992) 1.18
Human immunodeficiency virus (HIV) and JC virus in acquired immune deficiency syndrome (AIDS) patients with progressive multifocal leukoencephalopathy. Acta Neuropathol (1988) 1.16
Selective amplification of simian immunodeficiency virus genotypes after intrarectal inoculation of rhesus monkeys. J Virol (1994) 1.16